Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256326 | 0.83 | NPC1 (0.62) | L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11852932 | 0.81 | ALDH1A1 (0.61) | L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11845698 | 0.80 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| E1501 SCHEMBL28531202 | 0.79 | ALDH1A1 (0.79) | L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL560042 | 0.79 | MAPK1 (0.59) | L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17928599 | 0.79 | ALDH1A1 (0.63) | L3MBTL1ALDH1A1SMN1; SMN2TDP1THRB | |
| SCHEMBL11857838 | 0.79 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL941161 | 0.78 | CYP1A2 (0.56) | L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL31518753 | 0.78 | CYP2C19 (0.56) | L3MBTL1ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL19213900 | 0.78 | ALDH1A1 (0.42) | ALDH1A1RAB9ASMN1; SMN2CYP2D6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720445-B2 | PHENYLPROPIOLOYLOXYMETHYL ACETATE, FOR EXAMPLE; TREATING CANCER, HEMOLOGICAL DISORDERS AND INHERITED METABOLIC DISORDERS; INHIBITORS OF HISTONE DEACETYLASE | BEACON LABORATORIES, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6699902-B2 | ANTICANCER AGENTS | BEACON LABORATORIES, INC. | 2004-03-02 | — | — | US | disclosed |
| US-20020161045-A1 | NOVEL ACETYLOXYMETHYL ESTERS AND METHODS FOR USING THE SAME | ERRANT GENE THERAPEUTICS, LLC | 2002-10-31 | — | — | US | disclosed |
| US-20020119996-A1 | Novel acetyloxymethyl esters and methods for using the same | BEACON LABORATORIES, A DELAWARE CORPORATION | 2002-08-29 | — | — | US | disclosed |
| EP-1216984-A1 | Novel acetyloxymethyl esters and methods for using same | Beacon Laboratories, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119996-A1 | Novel acetyloxymethyl esters and methods for using the same | AADAC, ACAT1, EP300 | L3MBTL1 494/4885ALDH1A1 211/4885RAB9A 2727/4885 |
| US-20020161045-A1 | NOVEL ACETYLOXYMETHYL ESTERS AND METHODS FOR USING THE SAME | AADAC, ACAT1, EP300 | L3MBTL1 494/4885ALDH1A1 211/4885RAB9A 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.